Linezolid use for the treatment of multidrug-resistant tuberculosis, TB centers of excellence, United States, 2013–2018
Background: In 2019, the World Health Organization released guidelines reflecting major changes in multidrug-resistant tuberculosis (MDR-TB) management—prioritizing fluoroquinolones, bedaquiline, and linezolid (LZD) while de-emphasizing previously favored injectable agents. In some cases, linezolid...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-02-01
|
Series: | Journal of Clinical Tuberculosis and Other Mycobacterial Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405579420300656 |